Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome : a nationwide survey
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVES: Patients with APS and triple-positive for aPL are at high risk of recurrent events. As COVID-19 and COVID-19 vaccination may induce thrombotic complications, the objective of the study was to assess the course of COVID-19 and adverse events after vaccination in these patients.
METHODS: This is a nationwide multicentre survey conducted in nine APS referral centres by means of a questionnaire. Included patients are thrombotic APS with triple-positive aPL confirmed 12 weeks apart. Reference specialist physicians used a four-graded scale of severity for COVID-19 [from 0 (asymptomatic) to 3 (hospitalization in intensive care unit)] and a six-graded scale for adverse reactions to vaccination [from 0 (transient local injection site sign/symptoms) to 5 (potentially life-threatening reactions)]. Outcomes were considered within a 30-day period.
RESULTS: Out of 161 patients interviewed, 18 (11%) had COVID-19. All of them fully recovered without any progression to severe disease nor thromboembolic event. A total of 146 patients received the first (92%) and 129 (80%) the second dose of vaccine; side effects were minimal and, in most cases (83% after the first and 68% after the second vaccination) limited to a sore arm. Fifteen patients (9%) were unvaccinated. Most of them raised doubts on the need for vaccination, complained of poor safety and in general were reluctant about COVID-19 vaccination.
CONCLUSION: Patients with triple-positive thrombotic APS did not suffer from severe COVID-19 outcomes. Importantly, COVID-19 vaccination was well tolerated. These data may reassure patients and physicians and contribute to reducing hesitancy in unvaccinated patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 61(2022), SI2 vom: 28. Juni, Seite SI136-SI142 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pengo, Vittorio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
APS |
|---|
| Anmerkungen: |
Date Completed 30.06.2022 Date Revised 11.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keac224 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339421754 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339421754 | ||
| 003 | DE-627 | ||
| 005 | 20231226002847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keac224 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339421754 | ||
| 035 | |a (NLM)35412604 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pengo, Vittorio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome |b a nationwide survey |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2022 | ||
| 500 | |a Date Revised 11.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: Patients with APS and triple-positive for aPL are at high risk of recurrent events. As COVID-19 and COVID-19 vaccination may induce thrombotic complications, the objective of the study was to assess the course of COVID-19 and adverse events after vaccination in these patients | ||
| 520 | |a METHODS: This is a nationwide multicentre survey conducted in nine APS referral centres by means of a questionnaire. Included patients are thrombotic APS with triple-positive aPL confirmed 12 weeks apart. Reference specialist physicians used a four-graded scale of severity for COVID-19 [from 0 (asymptomatic) to 3 (hospitalization in intensive care unit)] and a six-graded scale for adverse reactions to vaccination [from 0 (transient local injection site sign/symptoms) to 5 (potentially life-threatening reactions)]. Outcomes were considered within a 30-day period | ||
| 520 | |a RESULTS: Out of 161 patients interviewed, 18 (11%) had COVID-19. All of them fully recovered without any progression to severe disease nor thromboembolic event. A total of 146 patients received the first (92%) and 129 (80%) the second dose of vaccine; side effects were minimal and, in most cases (83% after the first and 68% after the second vaccination) limited to a sore arm. Fifteen patients (9%) were unvaccinated. Most of them raised doubts on the need for vaccination, complained of poor safety and in general were reluctant about COVID-19 vaccination | ||
| 520 | |a CONCLUSION: Patients with triple-positive thrombotic APS did not suffer from severe COVID-19 outcomes. Importantly, COVID-19 vaccination was well tolerated. These data may reassure patients and physicians and contribute to reducing hesitancy in unvaccinated patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a APS | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a thrombosis | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Del Ross, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Tonello, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Gresele, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestri, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Simioni, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Campello, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Hoxha, Ariela |e verfasserin |4 aut | |
| 700 | 1 | |a Falanga, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ghirarduzzi, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Denas, Gentian |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 APS collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Semeraro, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Bertocchi, Stefania |e investigator |4 oth | |
| 700 | 1 | |a Paciullo, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Veropalumbo, Maria Rosaria |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 61(2022), SI2 vom: 28. Juni, Seite SI136-SI142 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:SI2 |g day:28 |g month:06 |g pages:SI136-SI142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keac224 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e SI2 |b 28 |c 06 |h SI136-SI142 | ||